

Genetic answers shouldn't come with cost barriers

GeneDx works directly with families to help make testing costs transparent and affordable so you can focus on care, not cost.

With broad insurance coverage and personalized billing support, families can move forward with testing confidently.



90%

of patients had an out-of-pocket cost of \$0-\$100 after insurance for outpatient exome or genome testing^{1,2}

GeneDx access solutions

GeneDx works directly with families to navigate coverage, understand costs, and explore affordability options, so your team can spend less time managing cost conversations and more time focused on care.

GeneDx accepts all commercial insurance, Medicaid, Medicare, and TRICARE, and is in-network with most national and regional health plans across the U.S.³



Flexible financial support

GeneDx's generous Financial Assistance Program makes testing more affordable. **Eligible families will pay between \$0 and \$250.**

Qualification is based on household size and income, with no extensive documentation or credit check required.



Personalized, interest-free payment plans

Our team works one-on-one with families to create **flexible, interest-free payment plans** tailored to their needs, so they can move forward with testing confidently.



For select rare disease indications, GeneDx also offers Accelerating Answers Programs that may reduce or eliminate patient costs.

Scan the QR code or visit genedx.co/patient-financial-support to explore access programs.

References: 1. Based on GeneDx 2025 internal data for outpatient exome and genome sequencing tests for patients with any form of insurance. Excludes inpatient and NICU testing. Historical results do not guarantee patient responsibility. 2. Patient out of pocket responsibility may vary by insurance coverage, deductible and coinsurance status, medical necessity review, payer policy, and financial assistance eligibility. 3. Includes payors with a contracted laboratory service agreement. Internal review of payors January 2026. Based on covered lives data of >99% of US covered commercial and Medicaid lives from Policy Reporter database accessed July 2025